COL1A2 and Myocardial fibrosis: Beyond mortality benefits, spironolactone therapy was linked to reductions in myocardial fibrosis markers such as procollagen type I and type III amino terminal peptides (PINP and PIIINP), suggesting decreased pathological remodeling of the cardiac extracellular matrix, which correlated with improved patient outcomes [24].